The Latest Breaking News from argenx

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases.  According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

Argenx SE (NASDAQ: ARGX) announced 

Here's a roundup of top developments in the biotech space over the last 24 hours:

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster. 

Argenx SE (NASDAQ: ARGX) ) has 

Here's a roundup of top developments in the biotech space over the last 24 hours:

argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:

  argenx (NASDAQ:ARGX) reported its Q4 earnings results on Thursday, March 3, 2022 at 01:00 AM. Here's what investors need to know about the announcement.